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AUTOPHAGY CELL BIOLOGY
Key Autophagy Machinery
Autophagy (macroautophagy) is a degrada-
tion process that delivers cytoplasmic materials
to lysosomes. By doing so, autophagy sustains
cellular renovation and homeostasis by recy-
cling molecular building blocks (such as amino
acids or fatty acids) for anabolic processes. The
first morphologically recognizable autophagic
precursor is a flat, double-membraned, sac-like
structure (called a phagophore), whose edges
elongate and fuse while engulfing a portion of
the cytoplasm. The resulting structure is a
spherical double-membrane organelle, called the
autophagosome. The formation of autophago-
somes requires several steps (nucleation,
elongation, and closure) governed by conserved
proteins termed ATGs (AuTophaGy-related
proteins) (Mizushima, Yoshimori, & Ohsumi,
2011). Autophagy initiation and autophagosome
formation require multiple interactions between
different individual proteins and protein com-
plexes. For simplicity, these are referred to by
their abbreviated names in the following sections
and are described in full in Table 11.1.
During autophagosome formation, the
ATG8 ubiquitin-like family proteins are conju-
gated to the lipid phosphatidylethanolamine
(PE) in autophagosomal membranes.
Mammalian cells have six ATG8 orthologues;
the MAP1-LC3 (LC3) and GABARAP subfami-
lies. Lipidated ATG8 proteins have been used
to distinguish autophagosomes from other
cellular membranes (Itakura & Mizushima,
2010). Measuring the LC3 lipidation, scoring
the number of LC3 vesicles, and detecting the
degradation of long-lived proteins or damaged
organelles are the mainstay methods used for
monitoring autophagy (Itakura & Mizushima,
2010). However, this requires careful interpre-
tation since immune receptors engaged by
phagocytosed cargoes can also enable LC3
recruitment to single-membrane phagosomes
in a process called LC3-associated phagocyto-
sis (Sanjuan et al., 2007).
LC3/GABARAP lipidation requires a prote-
ase and two ubiquitin-like conjugation systems
(Ichimura et al., 2000; Mizushima et al., 1998) as
illustrated in Fig. 11.1. The first reaction involves
the conjugation of the proteins ATG12 to ATG5
in a reaction requiring the enzymatic activities of
ATG7 and ATG10. The ATG5-ATG12 conjugate
forms a complex with ATG16L1. The cysteine
protease ATG4 cleaves the C-terminus of LC3
exposing a glycine residue (LC3-I), which is acti-
vated by the ATG7 enzyme, initiating events for
the second conjugation reaction. In this second
reaction, the ATG12ATG5ATG16L1 complex,
through interaction with the ATG3, acts as the
E3-like ligase that determines the site of LC3 lipi-
dation and assists the transfer of LC3-I to PE to
form LC3-II (Ichimura et al., 2000). ATG8/LC3
proteins may assist in the expansion and closure
of autophagosomal membranes (Nakatogawa,
Ichimura, & Ohsumi, 2007) as well as in autop-
hagosomelysosome fusion and inner autopha-
gosomal membrane degradation (Nguyen et al.,
2016; Tsuboyama et al., 2016).
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TABLE 11.1 List of Abbreviations of Proteins, Complexes and Cellular Structures Involved in Autophagy
Abbreviation Full Name Function of Protein or Complex in Autophagy
AKT Protein kinase B Serine/threonine kinase
AMBRA-1 Activating molecule in Beclin-1-regulated
autophagy
Part of VPS34 complex
AMPK AMP-activated protein kinase Protein kinase complex
APP Amyloid precursor protein Membrane protein cleaved by secretases to form
Aβ peptide
ATGs AuTophaGy-related proteins
ATG3 AuTophaGy-related protein 3 E2-ligase-like enzymatic activity
ATG4 AuTophaGy-related protein 4 Cysteine protease
ATG7 AuTophaGy-related protein 7 E1-ligase-like enzymatic activity
ATG9 AuTophaGy-related protein 9 Organization of the preautophagosomal
structure/phagophore assembly site
ATG10 AuTophaGy-related protein 10 E2-ligase-like enzymatic activity
ATG12 AuTophaGy-related protein 12 Ubiquitin-like protein
ATG14 AuTophaGy-related protein 14 Part of VPS34 complex; regulates localization of
the complex
ATG16L1 complex Complex comprising ATG5, ATG12, ATG16L1 E3-ligase-like enzymatic activity
Beclin-1 Homologue of BEC-1 (C. elegans) and ATG6
(yeast)
Part of VPS34 complex
COPI Coatomer protein I Coat protein complex required for ER-Golgi
transport and early endosome formation
CREB cAMP response element-binding protein Transcription factor
DFCP1 Double FYVE-containing protein 1 Interact with phospholipids
E2F1 E2F transcription factor 1 Transcription factor
ER Endoplasmic reticulum
ERES ER-exit sites
ESCRT Endosomal sorting complexes required for
transport
Membrane remodeling
FAM134 Family with sequence similarity 134 Selective autophagy cargo receptor
FIP200 Focal adhesion kinase family interacting
protein of 200 kDa
Part of ULK1 complex
FOXO Forkhead box Transcription factor
FXR Farnesoid X receptor Nuclear receptor
FYVE Zinc-finger domain Binds and inserts into PI3P membranes
(Continued)
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TABLE 11.1 (Continued)
Abbreviation Full Name Function of Protein or Complex in Autophagy
GABARAP γ-Aminobutyric acid receptor-associated
protein
ATG8 homologue
LYNUS Lysosome nutrient-sensing
MAM Mitochondria-ER-associated membranes
MAP1-LC3 or LC3 Microtubule associated proteins 1A/1B light
chain 3
ATG8 homologue
mTOR Mechanistic target of rapamycin Protein kinase
mTORC1 mTOR complex 1; complex comprising mTOR,
RAPTOR, GβL
Kinase complex
NBR1 Neighbor Of BRCA1 gene 1 Selective autophagy cargo receptor
NCOA4 Nuclear receptor coactivator 4 Selective autophagy cargo receptor
NF-κB Nuclear factor kappa-light-chain-enhancer of
activated B cells
Transcription factor (protein complex)
NDP52/
CALCOCO2
Nuclear domain 10 Protein 52/calcium
binding and coiled-coil domain 2
Selective autophagy cargo receptor
OPTN Optineurin Selective autophagy cargo receptor
P53/TP53 Tumor protein 53 Transcription factor (tumor suppressor)
p62/SQSTM1 Ubiquitin-binding protein P62/sequestosome1 Selective autophagy cargo receptor
PARKIN Parkinson’s disease protein 2 (PARK2) E3-Ubiquitin Protein Ligase
PE Phosphatidylethanolamine Phospholipids found in membranes
PI3P Phosphatidylinositol 3-phosphate Phospholipids found in membranes
PINK1 PTEN-induced putative kinase 1 (PARK6) mitochondrial serine/threonine-protein kinase
PPARα Peroxisome proliferation factor-activated
receptor α
Transcription factor
RAPTOR Regulatory-associated protein of mTOR Part of mTOR Complex 1
RE Recycling endosome
RPN10 26S proteasome regulatory subunit RPN10 Proteasome component
SNARE SNAP (soluble NSF attachment protein)
Receptor
Mediate vesicle fusion
SNX18 Sorting nexin 18 Membrane remodeling
TAX1BP1 Tax1 (human T-cell leukemia virus type I)
binding protein 1
Selective autophagy cargo receptor
TBC1D14 TBC1 domain family member 14 Membrane remodeling
TFEB Transcription factor EB Transcription factor
(Continued)
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ATGs are Organized in Signaling Modules
Upstream of LC3 Conjugation
The ULK1/2-complex is one of the most
upstream signaling units in autophagosome for-
mation. This complex includes the ULK1/2
homologues, ATG13, ATG101, and FIP200.
AMP-activated protein kinase (AMPK) phos-
phorylates ATG13 and FIP200 (components of
the ULK1/2-complex) and AMBRA-1 and
Beclin-1 (components of the VPS34 complex),
thereby targeting these two complexes to the
preautophagosomal membrane (see Fig. 11.2) (Di
Bartolomeo et al., 2010; Egan et al., 2015; Itakura
& Mizushima, 2010; Jung et al., 2009; Park, Jung
et al., 2016; Russell et al., 2013).
The generation of the lipid phosphatidylinosi-
tol 3-phosphate (PI3P) by the VPS34 complex at
the phagophore initiation site aids the recruit-
ment of PI3P-binding ATGs, such as DFCP1 and
ATG18/WIPIs family proteins (Proikas-Cezanne,
Takacs, Donnes, & Kohlbacher, 2015). WIPI2 is
crucial for the localization of ATG16L1 complex
TABLE 11.1 (Continued)
Abbreviation Full Name Function of Protein or Complex in Autophagy
TIP60 60 kDa Tat-interactive protein (K-
acetyltransferase 5, KAT5)
Acetyl transferase
TOLLIP Toll interacting protein Selective autophagy cargo receptor
TRAF6 TNF receptor-associated factor 6 E3-ubiquitin protein ligase
TRIM Tripartite motif Pathogen recognition
UBD Ubiquitin-binding domain Recognize and bind to ubiquitin
ULK1 and ULK2 Mammalian homologs of the C. elegans
uncoordinated 51 kinase
serine/threonine kinase
ULK1/2-complex Complex comprising ULK1/2, ATG13,
ATG101, and FIP200
Regulation of autophagosome biogenesis
VAMPs Vesicle-associated membrane proteins Mediate vesicle fusion
VPS Vacuolar protein sorting-associated protein Vesicular transport
VPS34 complex Complex comprising Beclin-
1ATG14VPS15VPS34
Class III phosphoinositide 3-kinase (PI3K)
VTI1B Vesicle transport through interaction with t-
SNAREs homolog 1B
Mediate vesicle fusion
WASH WASP and Scar homologue Vesicle trafficking
WDR45 WD repeat domain phosphoinositide-
interacting protein 45
Interacts with PI3
WIPIs WD-repeat protein interacting with
phosphoinositides (homologues of ATG18)
Interact with phospholipids
ZKSCAN3 Zinc-finger protein with KRAB and SCAN
domains 3
Transcription factor
Autophagy initiation and autophagosome formation requires multiple interactions between different individual proteins and protein
complexes. For simplicity, these are referred to by their abbreviated names in the text. These proteins and complexes have many diverse
cellular functions other than those involved in autophagy; only their main role in autophagy is described here.
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and dictates where the LC3 lipidation occurs
(Dooley et al., 2014). Together with ULK1, WIPI2
may influence the localization of both mATG9
and ATG2A/B. mATG9, the only transmem-
brane protein among the core ATGs, is consid-
ered one of the suppliers of lipid bilayers to the
initiation membrane during elongation (Orsi
et al., 2012; Papinski et al., 2014), while ATG2A/
B regulates autophagosome closure through fis-
sion/scission-type events (Knorr, Lipowsky, &
Dimova, 2015; Velikkakath, Nishimura, Oita,
Ishihara, & Mizushima, 2012).
Autophagosome Membrane Trafficking
Events
The membrane source for autophagosome
formation remains a key open question in the
field. Membranes from different organelles are
believed to contribute to autophagosome for-
mation by meeting in a particular subcellular
compartment representing the autophagosome
platform or “isolation membrane.” The isola-
tion membrane is a compartment in proximity
to mitochondria-endoplasmic reticulum
Structural units
Enzymatic units
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Atg12
Atg12
Atg5
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FIGURE 11.1 Conjugation steps involved in the regulation of autophagy. Two conjugation systems are required
for phagophore/autophagosome membrane elongation resulting in the formation of the ATG12-5-16 complex and
LC3-II. Structural components are represented as squares, and enzymatic components are represented as circles.
Initial conjugation of ATG12 and ATG5 is mediated by the enzymatic activity of ATG7 and ATG10. ATG5 interacts
with ATG16, generating the ATG12-5-16 conjugate, which then homo-oligomerizes to form a tetrameric structure
called ATG12-5-16 complex. LC3 is cleaved by ATG4 exposing a glycine residue and generating LC3-I, which is
activated by ATG7. The ATG12-5-16 complex through ATG3 interaction covalently conjugates LC3-I to PE to form
LC3-II. WIPI 2 modulates the localization of the ATG12-5-16 complex through PI3P, facilitating the interaction
of LC3-I with PE and its lipidation in the autophagosomal membrane. PE, phosphatidylethanolamine; PI3P, phospha-
tidylinositol 3-phosphate.
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(ER)-associated membranes (MAMs)
(Hamasaki et al., 2013; Hayashi-Nishino et al.,
2009) and is labeled by ATG14, DFCP1, and
WIPI2 (Axe et al., 2008; Proikas-Cezanne et al.,
2015). Contact sites between the isolation mem-
brane and surrounding organelles might
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Atg13 ULK1/2
Atg101
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Vps
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Vps
15
P P
Atg
14
LC3II
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Structural units
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Upstream signalling in autophagosome formation
Aa
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Transcriptional 
activation
TSC1 TSC2
RheB
Akt
Vps34 
complex
WIPI2
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P
P
P
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FIGURE 11.2 Initiation complexes controlling the initiation of autophagy. Many different cellular signals such as level
of nutrients, ATP, or cellular stress control autophagy by modulating mTORC1 activity. The activation of the Akt and
the presence of amino acids detected by Rag GTPases induce mTORC1 which in turns inhibits both Vps34 and ULK1/2
complexes and hence inhibiting autophagy. Conversely, deprivation of glucose or ATP promotes autophagy by activating
AMPK, which directly phosphorylates and induces VPS34 and ULK1/2 complexes. Moreover, AMPK inactivates mTORC1
either directly or through TSC1/TSC2, removing inhibition from ULK1/2-complex. Cell stress, modulated by factors like p53
or NFκB, transcriptionally activates proautophagy genes such as TSC1/TSC2 and ULK1/2 and, therefore, inducing
autophagy. The formation of the phagophore as a preautophagosomal structure requires the serial recruitment of ULK1/2-
complex first and VPS34 complex after, which generates PI3P, crucial for autophagosome formation. mTORC1, mTOR
complex; AMPK, AMP-activated protein kinase; PI3P, phosphatidylinositol 3-phosphate.
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contribute to the completion of the autophago-
some (Biazik, Yla-Anttila, Vihinen, Jokitalo, &
Eskelinen, 2015). Different sources have been
proposed as donor membranes including the
ER, MAM, ER-exit sites, the ER-Golgi interme-
diate compartment, recycling endosomes (REs),
Golgi, and plasma-membrane (Axe et al., 2008;
Biazik et al., 2015; Ge, Melville, Zhang, &
Schekman, 2013; Ge, Zhang, & Schekman,
2014; Graef, Friedman, Graham, Babu, &
Nunnari, 2013; Itakura & Mizushima, 2010;
Karanasios et al., 2016; Knaevelsrud et al.,
2013; Longatti et al., 2012; Park, Jung et al.,
2016; Puri, Renna, Bento, Moreau, &
Rubinsztein, 2013; Ravikumar, Moreau,
Jahreiss, Puri, & Rubinsztein, 2010; Shibutani
& Yoshimori, 2014; Tan et al., 2013; Yla-
Anttila, Vihinen, Jokitalo, & Eskelinen, 2009).
The endocytic compartment is believed to
play a primary role in autophagosome forma-
tion. The ATG16L1 complex and mATG9 travel
on independent clathrin-coated vesicles, and
these vesicles fuse in the REs in a VAMP3-
dependent manner. The trafficking of these
proteins from plasma-membrane to RE traffick-
ing and subsequent vesicle fusion are essential
for autophagy (Moreau, Ravikumar, Renna,
Puri, & Rubinsztein, 2011; Puri et al., 2013;
Ravikumar et al., 2010). The contribution of
REs to autophagosome formation is supported
by studies showing that autophagic proteins
(e.g., ULK1 and LC3) localize on the RE and
that the overexpression of RE-resident
proteins (e.g., TBC1D14 and SNX18) interfere
with the trafficking of mATG9 and ATG16L1
(Knaevelsrud et al., 2013; Lamb et al., 2016;
Longatti et al., 2012).
Key Signaling Pathways
Low cellular energy and nutrient states signal
to the autophagy pathway by posttranslation-
ally modifying autophagy-initiating complexes
or by regulating the transcription of core
autophagy genes. The energy-sensing AMPK
and the growth factor-regulated and nutrient-
sensing kinase mammalian target of rapamycin
(mTOR) oppositely regulate the ULK1/2 and
VPS34 complexes (Kim et al., 2013; Kim,
Kundu, Viollet, & Guan, 2011; Yuan, Russell, &
Guan, 2013), and thereby autophagy, through a
series of phosphorylation events.
AMPK is activated in response to low nutri-
ents (glucose) and low energy (ATP) (Kim et al.,
2013). AMPK allosteric activation by AMP
binding and phosphorylation of a conserved
threonine residue (Thr172) promotes autop-
hagy by directly activating ULK1 through
phosphorylation of Ser 317 and Ser 777 (under
glucose starvation) (Kim et al., 2011) or Ser 555
(under nutrient starvation and mitophagy)
(Yuan et al., 2013). AMPK activates the proau-
tophagy VPS34 complex by phosphorylating
Beclin-1 at Ser91/Ser94 (Orsi et al., 2012).
The mTOR complex 1 (mTORC1) is acti-
vated by nutrients (amino acids sensed by the
Rag GTPases) and growth factors (signaling by
receptor tyrosine kinases and the PI3K/Akt
pathway) (Laplante & Sabatini, 2012). Under
nutrient sufficiency, active mTORC1 inhibits
autophagy by binding the ULK1/2-complex,
(via raptor-ULK1/2 association) and phosphor-
ylating ATG13 and ULK1 at Ser 757 (i.e., a
different site from that phosphorylated by
AMPK). This suppresses ULK1/2 kinase
activity and prevents the ULK1AMPK inter-
action (Ganley et al., 2009; Hosokawa et al.,
2009; Jung et al., 2009; Kim et al., 2011). Under
nutrient starvation, mTORC1 dissociates from
the ULK1/2-complex, resulting in ULK1 activa-
tion, autophosphorylation, and phosphorylation
of ATG13 and FIP200, leading to the autophago-
some formation (Ganley et al., 2009; Jung et al.,
2009; Kim et al., 2011). mTORC1 also inhibits
the phosphoinositide 3-kinase activity of the
proautophagy VPS34 complex by phosphorylat-
ing ATG14 (Velikkakath et al., 2012). Additional
posttranslational modifications that increase
ULK1 activity after different inducing stimuli
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include ubiquitination, through the E3-ligase
TRAF6 (Nazio et al., 2013), and acetylation, by
the acetyltransferase TIP60 (Lin et al., 2012).
A plethora of transcription factors integrate a
wide range of cellular stimuli to induce core
autophagy-related genes expression (Fullgrabe,
Klionsky, & Joseph, 2014). Among the
autophagy-associated transcription factors, the
transcription factor EB (TFEB) (Sardiello et al.,
2009; Settembre et al., 2011) has a prominent role,
as its overexpression alone is sufficient to induce
autophagy and to ameliorate the phenotype of
neurodegenerative diseases (Decressac et al.,
2013; Tsunemi et al., 2012) and lysosomal storage
disorders (LSDs) in vivo (Medina et al., 2011;
Spampanato et al., 2013). TFEB connects the lyso-
some nutrient-sensing machinery to the transacti-
vation of autophagy-related genes (Settembre
et al., 2012). Under fed conditions, TFEB is phos-
phorylated by mTORC1, which leads to its reten-
tion in the cytosol. When autophagy is induced,
through the inhibition of mTORC1, TFEB
becomes dephosphorylated and translocates to
the nucleus (Roczniak-Ferguson et al., 2012).
Other well established transcriptional
regulators of autophagy include the FOXO fam-
ily, p53, E2F1, and NF-κB (Hayashi-Nishino
et al., 2009). More recently, the farnesoid
X receptor (FXR)/peroxisome proliferation
factor-activated receptor α (PPARα)/cyclic
adenosine monophosphate (cAMP) response
element-binding protein (CREB) axis was
discovered as a regulator of a plethora of core
autophagy-related genes. Under fed
conditions, the nuclear receptor FXR acts as a
transcriptional repressor, while autophagy
induction by starvation leads to the activation
of CREB and PPARα (Lee et al., 2014;
Seok et al., 2014).
Selective Autophagy
Stress-induced autophagy is thought to be
nonselective, leading to bulk degradation of
cytoplasm. However, autophagy contributes to
intracellular homeostasis in fed conditions by
selectively degrading long-lived proteins or
damaged organelles, recognized by specific
autophagy receptors (Shaid, Brandts, Serve, &
Dikic, 2013; Svenning & Johansen, 2013).
Selective autophagic pathways are generally
named after the cargo destined for degradation
and include aggrephagy (protein aggregates),
mitophagy (mitochondria), xenophagy (patho-
gens) (Deretic, Saitoh, & Akira, 2013; Melser,
Lavie, & Benard, 2015; Randow & Youle, 2014;
Rogov, Dotsch, Johansen, & Kirkin, 2014; Sorbara
& Girardin, 2015), ER-phagy (ER) (Khaminets
et al., 2015; Mochida et al., 2015), ferritinophagy
(ferritin) (Dowdle et al., 2014; Mancias, Wang,
Gygi, Harper, & Kimmelman, 2014), pexophagy
(peroxisomes) (Kim, Hailey, Mullen, &
Lippincott-Schwartz, 2008), ribophagy (ribo-
somes) (Kraft, Deplazes, Sohrmann, & Peter,
2008), and lipophagy (lipid droplets) (Singh et al.,
2009). Autophagy receptors are generally consid-
ered as either ubiquitin-dependent or ubiquitin-
independent (Khaminets, Behl, & Dikic, 2016).
Aberrantly folded or unused proteins are ubi-
quitinated, aggregated, and sequestered
by proteins containing an ubiquitin-binding
domain (i.e., p62/SQSTM1, NBR1, OPTN,
TAX1BP1, NDP52/CALCOCO2, TOLLIP, and
RPN10) that deliver them to lysosomes via
autophagy (Bjorkoy et al., 2005; Kirkin, Lamark,
Johansen, & Dikic, 2009; Lu, Psakhye, & Jentsch,
2014; Marshall, Li, Gemperline, Book, & Vierstra,
2015; Newman et al., 2012; Pankiv et al., 2007;
Thurston, Ryzhakov, Bloor, von Muhlinen, &
Randow, 2009; Wild et al., 2011).
Mitophagy is responsible for disposal of
dysfunctional mitochondria. Multiple signals
trigger mitophagy, including hypoxia and ery-
throid differentiation. PTEN-induced putative
kinase 1 (PINK1) and PARKIN, proteins
encoded by two genes that are mutated in
autosomal recessive Parkinson’s disease (PD),
enable forms of mitophagy. This pathway is
activated by nonhypoxic mitochondrial
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damage and linked to neurodegenerative dis-
eases, such as PD and amyotrophic lateral scle-
rosis (ALS) (Hamacher-Brady & Brady, 2015;
Liu et al., 2012; Melser et al., 2015; Pickrell
et al., 2015; Sandoval et al., 2008). In response
to mitochondrial damage, PINK1 is stabilized
on the mitochondrial outer membrane and
phosphorylates both cytoplasmic PARKIN and
ubiquitin on mitochondria (Cunningham et al.,
2015; Kane et al., 2014; Kazlauskaite et al., 2014;
Kondapalli et al., 2012; Koyano et al., 2014;
Ordureau et al., 2014). p62, OPTN, TAX1BP1,
and NDP52 work as ubiquitylated mitochon-
drial protein receptors (Heo, Ordureau, Paulo,
Rinehart, & Harper, 2015; Lazarou et al., 2015;
Wong & Holzbaur, 2014).
Cytosolic bacteria can also be ubiquitylated
and degraded by autophagy as a part of the
innate immune response. Several E3 ligases
attach ubiquitin chains to intracellular patho-
gens, for example, PARKIN on Mycobacterium
tuberculosis (Manzanillo et al., 2013) and Lrsm1
on Salmonella enterica (Huett et al., 2012).
Furthermore, Salmonella-containing endosomes
can undergo ubiquitination, which recruits the
autophagic machinery and ultimately incorpo-
rates them into autophagosomes (Fujita et al.,
2013). Similarly, different members of the
tripartite motif protein family have been
linked to xenophagy (Kimura et al., 2015;
Mandell et al., 2014).
A growing class of ubiquitin-independent
selective autophagy pathways have been
described (Khaminets et al., 2016), such as
NCOA4-mediated ferritinophagy (Dowdle
et al., 2014; Mancias et al., 2014) and FAM134-
dependent ER-phagy (Khaminets et al., 2015),
that appear specialized for degradation of one
substrate cargo.
Lysosomes
Whilst the signaling pathways and machin-
ery for the generation and trafficking of
autophagosomes are important, arguably the
key organelle in this process is the lysosome,
since it plays a crucial role in maintaining the
balance of cellular metabolism and growth by
continuously mediating anabolic and catabolic
processes. First described by Christian de
Duve, the lysosome is a cellular organelle
made of a single-lipid bilayer membrane and
an acidic lumen (de Duve, 2005), which
contains a complex machinery of hydrolases
that are responsible for the catabolism of a vast
range of substrates (Luzio, Pryor, & Bright,
2007; Saftig & Klumperman, 2009; Schroder,
Wrocklage, Hasilik, & Saftig, 2010). The major-
ity of extracellular substrates are transported to
the lysosome via the endocytic pathway, and
in particular through the fusion of the lyso-
some with late endosomes (Conner & Schmid,
2003; Huotari & Helenius, 2011), whereas intra-
cellular substrates reach the lysosome via fusion
of autophagosomes with lysosomes along the
autophagic pathway. The delivery of engulfed
cytosolic components is tightly coordinated so
that only fully formed autophagosomes fuse
with the endocytic system and deliver their
contents to the lysosome. In mammalian cells,
SNAREs, including VAMP7, VAMP8, and
VTI1B, mediate the lysosomal fusion of autop-
hagosomes (Fader, Sanchez, Mestre, &
Colombo, 2009; Furuta, Fujita, Noda, Yoshimori,
& Amano, 2010). SNAREs are membrane-
anchored proteins localized on opposing mem-
brane compartments that can interact with each
other to form a highly energetically favorable
complex. In order to drive membrane fusion,
SNAREs must form a trans-SNARE complex
consisting of one R-SNARE on the donor mem-
brane and three Q-SNAREs on the acceptor
membrane (Jahn & Scheller, 2006). As these
SNAREs are common to other intracellular
trafficking pathways, it can be difficult to assess
their specific roles in endocytosis and membrane
trafficking versus autophagy. The Q-SNAREs
syntaxin-7, syntaxin-8, and VTI1B, along with
the R-SNAREs VAMP7 and VAMP8, have
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been linked to the fusion of late endosomes
and lysosomes and thus play indirect roles in
autophagosome maturation (Pryor et al., 2004).
However, these SNAREs also function in
autophagosomal fusion. Indeed, VAMP8 and
VTI1B, but not VAMP7, syntaxin-7 or syntaxin-
8, were shown to be involved in autophagoso-
mal fusion during clearance of intracellular
bacteria (Furuta et al., 2010).
Autophagy in Neuronal Physiology
In the mouse, ubiquitous deletion of core
autophagy genes results in neonatal death
(Komatsu et al., 2005; Kuma et al., 2004; Sou
et al., 2008); however, conditional rescue of
autophagy in the nervous system can rescue this
lethality (Yoshii et al., 2016). The essential role of
autophagy in maintaining normal neuronal phys-
iology has been elucidated through disruption of
core autophagy genes using conditional knock-
out approaches. Neuronal depletion of ATG5,
ATG7, FIP200, or WIPI4 results in progressive
neurodegenerative phenotypes, an accumulation
of ubiquitinated and often p62/SQSTM1-positive
protein inclusions, cell death, and reduced
survival of the mice (Hara et al., 2006; Komatsu
et al., 2006; Komatsu, Waguri, Koike et al., 2007;
Liang, Wang, Peng, Gan, & Guan, 2010; Zhao
et al., 2015)[2-6]. However, there are differences
in the nature of the behavioral and pathological
changes observed depending on the autophagy
gene and cell type targeted.
Many of the original nervous system models
generated did not disrupt autophagy exclu-
sively in neurons. Depending on the promoter
used, such as Nestin-Cre, nonneuronal support
cells and neuronal stem cells were also targeted.
Hence, there has been continued focus on
more precise cellular autophagy disruption to
delineate its role within specific nervous system
cell types. This includes targeting subsets of
neuronal cell types (Chen et al., 2013; Kaushik
et al., 2011; Komatsu et al., 2006; Komatsu,
Wang et al., 2007; Nishiyama, Miura,
Mizushima, Watanabe, & Yuzaki, 2007; Zhou,
Doggett, Sene, Apte, & Ferguson, 2015) as
well as nonneuronal (e.g., Schwann) cells
(Gomez-Sanchez et al., 2015; Jang et al., 2016;
Jang et al., 2015). Studies disrupting core autop-
hagy genes in neural progenitor cells also pro-
vide an emerging area of focus, with autophagy
disruption resulting in reduced neural stem cell
survival and neuronal maturation (Lu et al.,
2014; Wang, Liang, Bian, Zhu, & Guan, 2013; Wu
et al., 2016; Xi et al., 2016; Yazdankhah, Farioli-
Vecchioli, Tonchev, Stoykova, & Cecconi, 2014).
In addition to knock-out studies, enhanced
tools are being developed to image and monitor
autophagy in vivo in normal and disease condi-
tions, for example, GFP-LC3 reporter mice and
more recently GFP-RFP-LC3 mice (Castillo,
Valenzuela et al., 2013; Mizushima, Yamamoto,
Matsui, Yoshimori, & Ohsumi, 2004; Pavel et al.,
2016). Furthermore, mouse models have been
generated to study mitophagy in vivo
(McWilliams et al., 2016; Sun et al., 2015) in spe-
cific cell types as well as under varied genetic
conditions such as Atg5 or Atg7 disruption. These
tools will enable measurement of howmitophagy
is modulated in broad genetic and pharmacologi-
cal conditions. They may be particularly useful
for PD, where there is extensive support for a
central role for autophagy/mitophagy disrup-
tion, mitochondrial damage, and an established
importance of the PINK1PARKIN pathway, as
reviewed (Pickrell et al., 2015).
AUTOPHAGY IN
NEURODEGENERATIVE DISEASES
Although the most common neurodegenera-
tive diseases are largely sporadic, mutations
that give rise to rare familial forms and genes
identified in GWAS studies have highlighted
how perturbation of autophagic processes
contribute to these diseases. Below, we discuss
the evidence for purturbed autophagy in the
pathogenesis of various neurodegenerative
diseases and the genetic factors that have been
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identified which may affect the efficiency
of autophagic processes in affected patients
(summarized in Fig. 11.3).
Alzheimer’s Disease
Alzheimer’s disease (AD), the most common
neurodegenerative disorder, is characterized by
the accumulation of intraneuronal tau tangles
and extracellular amyloid-beta (Aβ) deposits
called plaques. Whereas abundant Aβ deposits
are specific to AD, tau inclusions are also
characteristic of other neurodegenerative dis-
eases named tauopathies (Goedert & Spillantini,
2006). Aβ peptides are cleavage products of the
amyloid precursor protein (APP). In sporadic
cases, the accumulation of plaques appears to
result from impaired Aβ clearance, in contrast
with the overproduction of Aβ species in the
rare dominantly inherited forms of AD
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FIGURE 11.3 Schematic diagram of autophagosome formation and degradation. Genes that are known to play a role
in specific steps of the pathway and for which there are known clinical mutations are presented in the table below.
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(e.g., APP mutations) (Mawuenyega et al., 2010;
Potter et al., 2013). Downregulation of autop-
hagy can enhance AD pathogenesis in model
systems and similarly upregulation of the
autophagic system has been shown to reduce
Aβ levels in a number of models (Boland et al.,
2008; Ravikumar, Sarkar, & Rubinsztein, 2008;
Spilman et al., 2010; Tian, Bustos, Flajolet, &
Greengard, 2011; Vingtdeux et al., 2011).
Neurons from AD patients show an abnor-
mal accumulation of autolysosomes/lysosomes
(Nixon et al., 2005; Yu et al., 2005), and autop-
hagic failure by impaired autophagosome
formation or defective lysosomal clearance
appear to contribute to the increase of Aβ/tau
deposits and the development of AD features
in fibroblasts and brains from patients and
mouse models (Li, Zhang, & Le, 2010; Nixon &
Yang, 2011; Zhang, Chen, Huang, & Le, 2013).
Wild-type APP has been found in autophago-
somes, suggesting that autophagy might also
contribute to Aβ formation (Boland et al., 2008;
Yu et al., 2005). Mutations in Presenilin-1 (PS-1)
change the way APP protein is processed
into Aβ and are one of the main causes of
familial AD (Citron et al., 1997). However, PS-1
is also necessary for the v-ATPase-dependent
acidification of the lysosome, and PS-1 muta-
tions are associated with elevated lysosomal pH
that would be expected to affect its catabolic
activity (Coffey, Beckel, Laties, & Mitchell, 2014;
Lee et al., 2010; Wolfe et al., 2013). The
lysosomal endopeptidase Cathepsin D (CatD)
has also been implicated in the clearance of Aβ
and tau peptides through the autophagy-
lysosomal system. CatD has been found to colo-
calize with senile plaques of AD patients
(Cataldo, Hamilton, & Nixon, 1994; Cataldo &
Nixon, 1990; Khurana et al., 2010) and is involved
in the processing APP and apolipoprotein E, both
important factors in AD pathogenesis (Vidoni,
Follo, Savino, Melone, & Isidoro, 2016; Zhou,
Scott, Shelton, & Crutcher, 2006).
While the role of autophagy in degrading
Aβ has been extensively studied in
model systems (reviewed in Zare-Shahabadi,
Masliah, Johnson, & Rezaei, 2015), autophagy-
dependent secretion of Aβ into the extracellular
space has been also reported in APP transgenic
mice in which ATG7 is knocked out, suggest-
ing that autophagy might regulate plaque
formation (Nilsson et al., 2013). Indeed, the
autophagic markers LC3, ATG5, and ATG12
have been associated with Aβ plaques and tau
tangles in human brains (Ma, Huang, Chen, &
Halliday, 2010), and both APP and Aβ peptides
can be found within autophagosomes in AD
mouse models (Lunemann et al., 2007).
The clathrin adapter protein PICALM
(Phosphatidylinositol Binding Clathrin Assembly
Protein) has been shown to interact with LC3 and
target APP into autophagosomes (Tian, Chang,
Fan, Flajolet, & Greengard, 2013). Polymorphisms
in the PICALM gene are associated with
increased risk of AD. PICALM is a key compo-
nent of clathrin-mediated endocytosis, and loss of
function of this protein inhibits autophagy at
both the levels of autophagosome formation and
degradation and affects tau clearance in model
systems (Moreau et al., 2014). Recently, it has
been also reported that levels of this protein are
decreased in AD brains (Ando et al., 2013, 2016).
Depletion or downregulation of Beclin-1, an
autophagy initiator, promotes accumulation
and deposition of Aβ, leading to marked neu-
rodegeneration in both cell culture and mouse
models (Jaeger et al., 2010; Pickford et al.,
2008). Reduced levels of Beclin-1 have been
reported in the brains of AD patients
(Pickford et al., 2008; Small et al., 2005), and
these have been correlated with caspase 3 acti-
vation, which in turn cleaves Beclin-1 to a
fragment that becomes localized to plaque
regions and blood vessels in AD brains (Rohn
et al., 2011).
Tauopathies
Besides AD, the accumulation of tau protein
into intracellular tangles is the main feature
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of many other neuronal disorders termed tauo-
pathies, including progressive supranuclear
palsy (PSP), corticobasal degeneration (CBD),
or frontotemporal dementias (FTDs) (Lee,
Goedert, & Trojanowski, 2001). Degradation of
soluble tau depends on both the ubiquitin-
proteasome system and autophagy (Chesser,
Pritchard, & Johnson, 2013), whereas oligomers
and aggregates are mainly degraded by autop-
hagy (Boland et al., 2008; Lee, Lee, &
Rubinsztein, 2013). Hyperphosphorylated tau
colocalizes with the autophagosomal marker
LC3 and the autophagy cargo receptor p62/
SQSTM1 in tauopathy patients with CBD or
PSP (Piras, Collin, Gruninger, Graff, &
Ronnback, 2016). Some pathogenic tau muta-
tions, like P301L or A152T, impair proteasome
activity leading to the accumulation of ubiqui-
tinated proteins and small peptides in animal
models (Myeku et al., 2016) that can be amelio-
rated by inducing autophagy (Lopez et al.,
2017). Autophagy induction ameliorates the
pathological consequences of aberrant tau in
diverse experimental systems including pri-
mary neurons, Drosophila, zebrafish, and mice
(Berger et al., 2006; Caccamo et al., 2013;
Kruger, Wang, Kumar, & Mandelkow, 2012;
Lopez et al., 2017; Moreau et al., 2014;
Schaeffer et al., 2012).
Tau protein binds to and stabilizes microtu-
bules, which are the basic components
involved in axonal vesicle transport (Bernhardt
& Matus, 1984; Goedert, Wischik, Crowther,
Walker, & Klug, 1988; Millecamps & Julien,
2013). Mutations and/or hyperphosphorylation
of tau have been reported to impair the
dyneindynactin complex, leading to disrup-
tion of axonal transport and increasing the
number of autophagosomes in FTDs and AD
(Butzlaff et al., 2015; Kimura, Noda, &
Yoshimori, 2008; Lacovich et al., 2017; Majid
et al., 2014). Small tau fibrils can interact with
lysosomal membranes in vitro (Wang et al.,
2009) and disrupt their permeability, resulting
in lysosomal damage in a mouse model of AD
(Piras et al., 2016) and in AD patients (Perez
et al., 2015). Moreover, increased levels of lyso-
somal proteins LAMP1 and CatD have been
recently reported in CBD and PSP patients
(Piras et al., 2016).
Parkinson’s Disease
PD results in the progressive loss of dopami-
nergic neurons in the substantia nigra pars
compacta and is associated with the presence
of Lewy bodies, alpha-synuclein (α-syn)-
positive intracellular inclusions. Increased α-syn
levels, as a result of multiplication of the SNCA
gene encoding it, is sufficient to cause PD.
Overexpression of α-syn in cells and mice
impairs autophagy and results in mislocaliza-
tion of mATG9 (Winslow et al., 2010).
Accumulation of α-syn has also been
described for PD-associated mutations of
VPS35 (vacuolar protein sorting-associated
protein 35). VPS35 is a component of the retro-
mer complex that recruits actin nucleation-
promoting WASP and Scar homologue com-
plex to endosomes. The D620N mutation in
VPS35 causes autosomal-dominant PD and, in
transfected cells, has been shown to impair
autophagy, mislocalize mATG9 (Zavodszky
et al., 2014), and affect the trafficking of the
lysosomal protein LAMP2A, leading to α-syn
accumulation (Tang et al., 2015).
Heterozygous mutation of GBA1 is the most
common known genetic risk factor for PD.
GBA1 encodes glucocerebrosidase (GCase), a
lysosomal enzyme that cleaves the β-glucosyl
linkage of glucosylceramide (GlcCer). Deficiency
in GCase activity leads to accumulation of its
substrate in the lysosome and compromised
lysosomal activity. Loss of GCase activity, with
resultant increased GlcCer levels, leads to an
increase in α-syn levels in cultured neurons,
mouse, and human brain. Increased α-syn in
turn inhibits lysosomal maturation and GCase
activity, resulting in additional GlcCer
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accumulation and further α-syn accumulation
(Mazzulli et al., 2011). Even in sporadic PD with-
out GBA1 mutations, decreased lysosomal
GCase activity was directly related to reduced
lysosomal chaperone-mediated autophagy and
increased α-syn in the early stages of PD
(Murphy et al., 2014). Treatment of iPS-derived
dopaminergic (DA) neurons from PD patients
with a modulator of GCase enhanced GCase
activity and increased clearance of α-syn and
reversed lysosomal dysfunction (Aflaki, Borger
et al., 2016; Mazzulli et al., 2016). In the Thy1-
SNCA mouse model of PD, where mice express
mutant human A53T α-syn, ectopic expression
of GCase in the striatum led to a decrease in the
levels of α-syn and delayed the progression of
synucleinopathy (Rockenstein et al., 2016). In
addition to inhibition of the autophagy-
lysosomal pathway, GBA mutations activate the
unfolded protein response and lead to ER stress
(in fibroblasts and iPSC-derived DA neurons
from PD patients), which can be reversed by
small molecule chaperones in cells and
Drosophila, by improving GCase trafficking to
the lysosomes (Fernandes et al., 2016; Sanchez-
Martinez et al., 2016). Homozygous GBA muta-
tion causes Gaucher disease, an LSD, and chap-
erone treatment of Gaucher patient
macrophages induces autophagy, restoring
autophagosome maturation, and the fusion of
lysosomes with autophagosomes (Aflaki,
Moaven et al., 2016). The mechanism by which
GCase deficiency leads to reduced autophagy
and accumulation of α-syn has been proposed
to be as a result of altered lysosomal recycling,
via the process of autophagy-lysosome refor-
mation, resulting in the accumulation of
defective lysosomes (Magalhaes et al., 2016).
Mutation in ATP13A2, which encodes a
lysosomal P5-type ATPase that facilitates
cation transport, results in autosomal recessive
early-onset PD. Depletion of ATP13A2,
through modulation of synaptotagmin 11
levels, impairs lysosomal function and the deg-
radation of lysosomal substrates, resulting in
accumulation of α-syn (Bento, Ashkenazi,
Jimenez-Sanchez, & Rubinsztein, 2016; Dehay
et al., 2012). Although Atp13a2-deficient mice
do not exhibit degeneration of DA neurons or
significant accumulation of α-syn, subunit c of
mitochondrial ATP synthase accumulated in
abnormal lysosomes as a result of lysosomal
dysfunction and suggests that clearance of
damaged mitochondria may be impaired (Sato
et al., 2016). Additionally, trafficking to the
lysosome of CatD, which is known to
degrade α-syn, was decreased (Kett & Dauer,
2016). Studies of patient-derived cells show
Zn21 dyshomeostasis, mitochondrial dysfunc-
tion, and glycolytic dysfunction as a result of
loss of ATP13A2 (Park, Koentjoro, Davis, &
Sue, 2016).
Familial early-onset forms of PD are also
caused by recessive mutations in PARK2/
PARKIN (Kitada et al., 1998), encoding an E3-
ubiquitin ligase, and PINK1 (Valente et al.,
2004), encoding a serine-threonine kinase. As
described above, both proteins control mito-
phagy. Both PINK1 and PARKIN patient-
derived mDA neurons showed accumulation
of α-syn, increased susceptibility to mitochon-
drial toxins, mitochondrial dysfunction, and
increased intracellular DA levels (Chung
et al., 2016).
Mutations in the gene encoding leucine-rich
repeat kinase 2 are responsible for the majority
of inherited forms of PD as well contributing
to some cases of sporadic PD. Whilst the
exact function of the wild-type protein is not
fully understood, loss-of-function experimental
models suggest an important role in intracellu-
lar vesicle trafficking (reviewed in Roosen &
Cookson, 2016). However, clinical mutations
are spread throughout this multidomain pro-
tein, and it is unclear how these individual
mutations may affect protein function. For
example, the kinetics of autophagosome
formation and autophagosomelysosome
fusion has been shown to be disrupted in
G2019S iPSC-derived human neurons,
THE MOLECULAR AND CELLULAR BASIS OF NEURODEGENERATIVE DISEASES
313AUTOPHAGY IN NEURODEGENERATIVE DISEASES
resulting in delayed mitophagy (Hsieh et al.,
2016), and increased α-syn levels were found
in iPSC-derived DA neurons from PD patients
with the G2019S mutation, but not the R1441G
mutation. However, in the latter example,
impaired canonical NF-κB signaling was pro-
posed to be the mechanism, rather than autop-
hagy (Lopez de Maturana et al., 2016). In
G2019S knock-in mice, with abnormally ele-
vated excitatory synaptic activity and altered
postsynaptic morphology (Matikainen-Ankney
et al., 2016), no changes in α-syn were
observed, but increased levels of LC3-II were
reported (Yue et al., 2015). In contrast, R1441G
knock-in mice showed no difference in α-syn,
LC3B, or Beclin-1 expression, only perturbed
DA homeostasis (Liu, Lu et al., 2014).
Polyglutamine Disorders
Nine polyglutamine (polyQ) diseases are
caused by a mutation in the polyQ domain in dif-
ferent proteins that result in the expansion of the
polyQ tract. Examples include mutant huntingtin
in Huntington’s disease (HD), mutant ataxin-3 in
spinocerebellar ataxia type 3 (SCA3), other mutant
proteins in other spinocerebellar ataxias, and
mutant androgen receptor in spinal and bulbar
muscular atrophy (SBMA) (Gatchel & Zoghbi,
2005). Earlier age of disease onset is often corre-
lated with increasing length of the polyQmutation
(Andrew et al., 1993). The expansion of the polyQ
domain (usually more than 35 glutamines) results
in accumulation of the mutant proteins in oligo-
meric forms and aggregates in neurons that are
found in distinct regions in the brain (e.g., stria-
tum, cerebral cortex, and cerebellum) (Andrew
et al., 1993; Gatchel & Zoghbi, 2005; Rubinsztein,
2006). While neuronal toxicity is linked with
aggregate formation, toxicity is also observed in
neurons without aggregates (Arrasate, Mitra,
Schweitzer, Segal, & Finkbeiner, 2004).
Studies have described autophagy perturba-
tion in several polyQ diseases, often by
mechanisms that alter upstream signals
required for autophagy induction. For exam-
ple, the Ras homolog enriched in striatum
(Rhes) binds the autophagy initiation protein,
Beclin-1, and thus prevents the autophagy
inhibitory interaction of bcl-2 with Beclin-1
(Mealer, Murray, Shahani, Subramaniam, &
Snyder, 2014). Mutant huntingtin interacts
with Rhes and reduces the beneficial effect of
Rhes on Beclin-1 activation and autophagy
(Mealer et al., 2014). Wild-type huntingtin
serves as a scaffold or adaptor for selective
autophagy that is induced by cellular stresses
(Rui et al., 2015); therefore, mutant huntingtin
might also decrease the efficient recruitment of
autophagic cargo (Martinez-Vicente et al.,
2010). Furthermore, sequestration of Beclin-1
into polyQ aggregates is seen in models of HD,
SCA3, and SCA7 (Alves et al., 2014;
Nascimento-Ferreira et al., 2011; Shibata et al.,
2006) and might impair Beclin-1-autophagic
activity. Indeed, reduced Beclin-1 levels have
been observed in fibroblasts derived from
SCA3 patients (Onofre et al., 2016).
Interestingly, while Beclin-1 sequestration into
aggregates is likely to inhibit autophagy, the
formation of aggregates can also help neurons
to cope with polyQ toxicity (Ravikumar et al.,
2004). This is evident in studies observing the
sequestration of mTOR into aggregates in HD
and SCA7 mouse models (Alves et al., 2014;
Ravikumar et al., 2004), which is likely to
provide signals that induce autophagy to some
extent. However, the net effects of autophagy-
inducing versus -inhibitory signals are difficult
to discern at present and may vary at different
stages of disease. Since some autophagy
perturbations are influenced by the soluble
fraction of the mutant protein and some by its
aggregated forms, it also seems that the ratio
between the two fractions can affect the
outcome of autophagy in these diseases.
Recent data suggest that wild-type ataxin-3 is
a positive regulator of autophagy by acting as a
deubiquitinase for the core autophagy protein
Beclin-1, thereby protecting it from proteasome-
mediated degradation. The ataxin-3-Beclin-1
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interaction is enabled by the normal polyQ
stretch in ataxin-3. When this tract is enlarged
by the SCA3 mutation, the ataxin-3-Beclin-1 inter-
action is strengthened, but the deubiquitinase
activity is decreased. This may result in
a dominant-negative effect which lowers Beclin-1
levels and impairs autophagy in SCA3
(Ashkenazi et al., 2017). Interestingly, with other
polyQ expansion diseases (e.g., HD), at least in
cell lines and an animal model, there appears to
be competition in trans of the disease-causing
polyQ tract in the soluble protein with the inter-
action of ataxin-3 with Beclin-1. This results in a
modest impairment of starvation-induced autop-
hagy in these model systems, which may contrib-
ute to these diseases (Ashkenazi et al., 2017).
Another autophagy-associated protein that is
regulated by mutant ataxin-3 is the E3-ubiquitin
ligase PARKIN (Durcan et al., 2011). PARKIN
recruits damaged mitochondria for degradation
by autophagy (Narendra, Tanaka, Suen, & Youle,
2008) and reduced levels of parkin in the brain of
a transgenic mouse model of SCA3 might be
linked to disease pathogenesis (Durcan et al.,
2011). Some mutant polyQ proteins also perturb
transcriptional events that are important for
autophagy induction. For example, Sirtuin-1 dea-
cetylates several genes necessary for autophagy
induction (Huang et al., 2015; Lee et al., 2008),
and lower levels of Sirtuin-1 are observed in
SCA3 mouse model (Cunha-Santos et al., 2016).
Finally, mutant androgen receptor, which causes
SBMA, directly interacts with TFEB, a transcrip-
tion factor that coordinately regulates expression
of genes involved in lysosomal biogenesis and
key autophagy genes (Cortes et al., 2014;
Settembre et al., 2011). As a consequence of this
interaction, TFEB transactivation is abrogated
and autophagy is impaired (Cortes et al., 2014).
Amyotrophic Lateral Sclerosis
ALS is predominantly sporadic, although a
growing number of genes have been identi-
fied in familial forms. ALS-associated
mutations in TDP-43 (TAR DNA-binding pro-
tein 43), SOD1 (superoxide dismutase 1), FUS
(fused in sarcoma/translocated in sarcoma),
and C9ORF72 (Farg et al., 2014; Fecto &
Siddique, 2011; Watabe et al., 2014) result in
protein misfolding and the accumulation of
aggregates. These intracellular aggregates
correlate with an accumulation of autophago-
somes and decreased proteasome activity in
neurons of the spinal cord and brains in ALS
patients (Chen, Zhang, Song, & Le, 2012;
Cheroni et al., 2009). Growing evidence corre-
lates defects in the autophagy system with the
pathogenesis of ALS. The accumulation of the
ALS-related protein FUS has been positively
correlated with impaired autophagic flux
(Watabe et al., 2014). The list of novel muta-
tions in the Rab5 activator ALS2/Alsin that are
associated with motor disorders is expanding
(Daud et al., 2016; Siddiqi et al., 2014), and loss
of ALS2 has been associated with impaired
endosomal trafficking, decreased lysosome
protein degradation and neurodegeneration in
mouse models (Gautam et al., 2016; Hadano
et al., 2010).
Recognition of misfolded ubiquitinated
proteins by autophagy receptors enables selec-
tive autophagic sequestration of ubiquitinated
substrates. This mechanism is relevant to many
different proteins that are mutated in ALS.
Mutations in the autophagy cargo receptor
p62/SQSTM1 have been associated with
disrupted degradation of mutant SOD1 and
TDP-43 due to defective recognition of LC3-II
in cell and mouse models and also in patients
with ALS (Gal et al., 2009; Goode et al., 2016;
Mizuno et al., 2006; Ramesh Babu et al., 2008;
Teyssou et al., 2013). Similarly, clinical muta-
tions in the LC3-binding region of p62/SQSTM1,
such as L341V, also lead to the impairment of
its recruitment into autophagosomes (Goode
et al., 2016). Clinical mutations in the receptor
ubiquilin-2 also promote abnormal protein
accumulation (Williams et al., 2012;
Zhang, Yang, Warraich, & Blair, 2014) in
ubiquitin-positive inclusions together with
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mutant p62/SQSTM1 (Deng et al., 2011;
Williams et al., 2012; Zhang, Yang et al., 2014).
Similar results were seen for OPTN, another
autophagy receptor, where familial ALS-
related mutations compromise autophagosome
maturation, interaction with p62/SQSTM1, and
protein clearance (Maruyama et al., 2010; Shen,
Li, Chen, Chern, & Tu, 2015). Most of ALS-
associated mutations in OPTN are located in
its myosin VI-binding domain and alter autop-
hagosome trafficking (Shen et al., 2015;
Sundaramoorthy et al., 2015; Tumbarello et al.,
2012). The recent identification of ALS-
associated mutations in TANK-binding kinase
1 (Cirulli et al., 2015; Freischmidt et al., 2015)
identifies a link between two other familial
ALS-associated proteins, since this kinase
phosphorylates OPTN (Moore & Holzbaur,
2016) and p62/SQSTM1 (Pilli et al., 2012).
Various proteins required for endocytic traf-
ficking have also been implicated in ALS and
FTD. Alterations in C9ORF72 gene are the most
common cause of ALS and FTD and are linked
by common pathological features (DeJesus-
Hernandez et al., 2011; Winklhofer, Tatzelt, &
Haass, 2008). The wild-type protein is involved
in the regulation of endocytic transport and
colocalizes with the autophagic proteins Rab7
and Rab11 in human motor neurons (Farg
et al., 2014). C9ORF72 can interact with the
autophagy receptors p62/SQSTM1 and OPTN
via Rab8 and Rab39, and affects autophago-
some formation (Sellier et al., 2016). In addi-
tion, C9ORF72 mediates the translocation of
ULK1, a kinase controlling autophagosome for-
mation, to the phagophore via Rab1a (Webster
et al., 2016). It has been recently reported that
loss of C9ORF72 induces autophagy via mTOR
and TFEB signaling (Ugolino et al., 2016). In
addition to the coding sequence mutations in
multiple genes associated with ALS/FTD, epi-
genetic mechanisms could play a key role in
initiating ALS and FTD, especially for sporadic
cases (Belzil, Katzman, & Petrucelli, 2016). For
example, hypermethylation of the C9ORF72
promoter may have a protective function
against repeat length expansion that is associ-
ated with pathology (Liu, Russ et al., 2014).
Mutations in CHMP2B [charged multivesi-
cular body (MVB) protein 2B] and the sigma
nonopioid intracellular receptor 1
(SIGMAR1) have been associated with both
FTD and ALS (Al-Saif, Al-Mohanna, &
Bohlega, 2011; Krasniak & Ahmad, 2016;
Luty et al., 2010), and both proteins play a
role in vesicle trafficking. CHMP2B is essen-
tial for autophagosomeendosome fusion and
endolysosomal trafficking via endosomal sort-
ing complexes required for transport (ESCRT),
and defective function of this protein impairs
autophagosome degradation (Filimonenko
et al., 2010; Krasniak & Ahmad, 2016; West, Lu,
Marie, Gao, & Sweeney, 2015). Knockdown of
SIGMAR1 impairs vesicle trafficking from the
ER to the Golgi leading to reduced fusion
of autophagosomes with lysosomes and conse-
quently reduced degradation of autophagy
substrates (Vollrath et al., 2014).
Hereditary Spastic Paraplegias
Hereditary spastic paraplegia (HSP)
describes a heterogeneous group of inherited
neurodegenerative disorders pathologically
characterized by length-dependent axonal
degeneration of corticospinal tracts resulting in
progressive spasticity and weakness in the
lower limbs. The type of HSP is designated by
the loci it is associated with—to date, 50 spastic
paraplegia genes (SPGs) and more than 70
distinct loci (SPG1-72) have been identified
(Fink, 2013).
SPG11, encoding spatacsin, is the most
commonly mutated gene in autosomal reces-
sive HSPs. Spg112/2 mice have compromised
autophagic lysosome reformation in neurons
and a dramatic reduction in the number of
lysosomes in the Purkinje cells (Varga et al.,
2015), which result in impaired
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autophagosome clearance. Similarly, loss or
mutation of SPG15 (encoding spastizin) causes
defects in lysosomal biogenesis and autopha-
gosome maturation (Chang, Lee, & Blackstone,
2014; Renvoise et al., 2014). Spastizin also inter-
acts with the Beclin-1UVRAGRubicon mul-
tiprotein complex required for autophagosome
maturation (Vantaggiato et al., 2013). Thus, the
loss of spastizin in fibroblasts of HSP15 patients
or neuronal cells leads to compromised autop-
hagy flux due to the accumulation of immature
autophagosomes (Vantaggiato et al., 2013).
Additionally, depletion of the ESCRT compo-
nents, such as VPS37A (encoded by SPG53), is
also known to reduce the autophagy flux
(Ganley, Wong, Gammoh, & Jiang, 2011; Rusten
& Stenmark, 2009; Sahu et al., 2011).
To date, genes mutated in other SPGs have
not been shown to be directly involved in
regulating the overall autophagy flux or
autophagosome maturation, being required
only for specific types of autophagy. For
example, the deubiquitinating enzyme USP8
(SPG59) is directly involved in regulating
PARKIN deubiquitination, which is required
for its efficient recruitment to damaged mito-
chondria. Consequently, loss of USP8 results
in compromised parkin-mediated mitophagy
(Durcan et al., 2014).
A rare form of HSP is caused by recessive
mutations in SPG49, encoding TECPR2 (tecto-
nin β-propeller containing protein 2). TECPR2
is an ATG8-binding protein that cooperates
with lipidated LC3C to efficiently regulate the
ER-exit sites and ER export required for the
formation of early autophagosome structures
(Stadel et al., 2015). Loss of TECPR2 results
in reduced levels and lipidation of LC3,
TECPR2 being a positive regulator of autop-
hagy (Oz-Levi et al., 2012). Patient fibroblasts
with TECPR2 mutations show compromised
ER-exit and reduced autophagosome biogene-
sis (Stadel et al., 2015).
A very rare form of HSP (characterized
by mutilating sensory neuropathy) was identi-
fied in four patients from a consanguineous
Moroccan family, being caused by a loss-of-
function mutation in CCT5 (encoding the epsi-
lon subunit of the cytosolic chaperonin CCT/
TRiC) (Bouhouche, Benomar, Bouslam, Chkili,
& Yahyaoui, 2006). Recently, it has been shown
that CCT5 depletion in primary mouse cortical
neurons and Drosophila causes accumulation of
immature autophagosomes and undegraded
autophagic cargo, such as p62 and other
aggregate-prone proteins (Pavel et al., 2016).
This block in autophagy flux caused by CCT5
depletion is mainly due to reduced lysosomal
functioning through compromised actin cyto-
skeleton dynamics required for trafficking of
lysosomal enzymes and V-ATPase into the
lysosomes (Pavel et al., 2016).
Lafora Disease
Lafora disease is an autosomal recessive
disorder characterized by neurodegeneration
and abnormal accumulation of Lafora bodies
(LBs), which are polyglucosan bodies compris-
ing a long, hyperphosphorylated, and insolu-
ble form of glycogen. Lafora disease is caused
by mutations in the genes encoding either
laforin (Minassian et al., 1998), a dual specific-
ity phosphatase that dephosphorylates com-
plex carbohydrates, or malin (Chan et al.,
2003), an E3-ubiquitin ligase. Both proteins are
involved in the regulation of glycogen biosyn-
thesis. Several studies have revealed an impor-
tant role for autophagy in the modulation of
Lafora disease. Wild-type laforin can induce
autophagy (Aguado et al., 2010), and both
laforin and malin knock-out mice show
impaired autophagy (Aguado et al., 2010;
Criado et al., 2012), with an mTOR-dependent
mechanism in laforin knock-out mice.
As several reports demonstrated that
reducing glycogen synthesis resulted in pre-
vention of formation of LBs and neurodegen-
eration, it was unclear whether alteration of
autophagy was a cause or a consequence of
neurodegeneration. Duran, Gruart, Garcia-
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Rocha, Delgado-Garcia, and Guinovart (2014)
used an elegant in vivo approach to shed light
on this matter, demonstrating that autophagy
was not upregulated in malin knock-out mice
unable to synthesize glycogen in the brain.
These results suggest that the autophagy defect
seen upon malin knockout is a consequence of
glycogen accumulation (Duran et al., 2014).
Dynein and Dynamin Mutations
As described here, many of the common
neurodegenerative diseases are characterized by
dysfunctional vesicle trafficking. Cytoplasmic
dynein is the molecular motor that drives the
retrograde transport of cargoes in cells, acting
in concert with its activator dynactin. In the con-
text of autophagy, the dynein complex enables
retrograde trafficking of autophagosomes to
the part of the cell where lysosomes are clus-
tered, enabling autophagosomelysosome fusion.
Mutations in dynein heavy chain (DYNC1H1)
cause a wide range of neuromuscular degen-
erative diseases, including spinal muscular
atrophy and axonal CharcotMarieTooth
disease (Harms et al., 2012; Weedon et al.,
2011). Inhibition of dynein activity results in
decreased autophagosomelysosome fusion
and interferes with clearance of aggregate-
prone proteins in cells, Drosophila, and mice
(Ravikumar et al., 2005). Similar results were
obtained in human glioma cells, where chemi-
cal inhibition of dynein led to an accumulation
of autophagosomes indicative of impaired
autophagosomelysosome fusion (Yamamoto,
Suzuki, & Himeno, 2010). Missense mutations
in a dynactin gene (DCTN1), encoding the
p150Glued subunit of dynactin, have been
reported in familial and sporadic ALS (Puls
et al., 2003). Mutations in DCTN1 have been
shown to cause Perry syndrome, a progressive
neurodegenerative disorder that can present
Parkinsonism and psychiatric changes (Farrer
et al., 2009), suggesting a potential role for
autophagic dysfunction in this disease.
Dynamin 2 mutations cause dominant cen-
tronuclear myopathy (Bitoun et al., 2005) or
CharcotMarieTooth disease (Zuchner et al.,
2005). Dynamin 2 is a GTPase required for
endocytosis and is responsible for the pinching
off of nascent vesicles from intracellular mem-
branes. The Drosophila orthologue of dynamin
2, Shi, was shown to have a direct role in
autophagy, as it is required for lysosomal/
autolysosomal acidification (Fang et al., 2016).
Similar results are reported in knock-in mice
expressing the most frequent human dynamin
2 mutation. Embryonic fibroblasts from homo-
zygous knock-in mice showed an accumulation
of immature autophagosomes, probably due to
a defect in acidification (Durieux et al., 2012).
Diseases Resulting from Mutations
in Core Autophagy Genes
Recent advances in next-generation sequenc-
ing have led to the identification of a growing
number of autophagy-related genes showing
point mutations in neurodegenerative disease
patients. The majority of mutations linked to
late-onset neurodegenerative disease are found
in genes that are not part of the core autophagy
machinery but could rather be termed “autop-
hagy accessory” genes. However, recently,
some rare congenital neurodegenerative dis-
eases have been linked to mutations in genes
that play a central role in the autophagic pro-
cess (Menzies, Fleming, & Rubinsztein, 2015).
The first link between a core autophagy-
related gene was established in 2012 when de
novo mutations in WD-repeat domain 45
(WDR45) were associated to beta-propeller
protein-associated neurodegeneration (BPAN),
also referred to as static encephalopathy of
childhood with neurodegeneration in adult-
hood or neurodegeneration with brain iron
accumulation-5 (Haack et al., 2012; Saitsu et al.,
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2013). BPAN patients have global developmen-
tal delay in early childhood and progressive
dystonia, Parkinsonism, and dementia as
young adults. WDR45 encodes WIPI4, one of
the four mammalian homologs of the yeast
Atg18 protein (Lu et al., 2011). WIPI4 acts as an
autophagy-specific PI3P-binding effector and is
essential for autophagosome formation (Lu
et al., 2011). The BPAN-associated mutations in
WDR45 result in lower WIPI4 protein levels,
due to instability of the protein and therefore
accumulation of early autophagosomal mem-
branes and reduced autophagic flux (Saitsu
et al., 2013). Noteworthy, a central nervous sys-
tem (CNS)-specific knock-out of Wdr45 in a
mouse model replicated several aspects of
BPAN, including poor motor coordination,
impaired learning and memory, as well as
autophagy defects (Zhao et al., 2015).
While the link between Vici syndrome and
ectopic P-granules autophagy protein 5 (EPG5)
was discovered several years ago (Cullup
et al., 2013), the molecular function of EPG5 in
autophagy has only been characterized recently
(Wang et al., 2016). Vici syndrome is a rare
autosomal recessive congenital multisystem
disorder characterized by agenesis of the cor-
pus callosum, bilateral cataracts, cutaneous
hypopigmentation, progressive cardiomyopa-
thy, and variable immunodeficiency. The
affected individuals show psychomotor retar-
dation and hypotonia (del Campo et al., 1999;
Dionisi Vici et al., 1988). Most patients with
Vici syndrome have truncating, splice site, or
missense mutations in the EPG5 gene with no
clear mutational hotspot (Byrne et al., 2016).
EPG5 acts as a Rab7 effector that mediates
the fusion of autophagosomes with late
endosomes/lysosomes. Various tissues from
Vici patients as well as Epg5 knock-out
mice display accumulation of nondegradative
autophagic vacuoles (Wang et al., 2016; Zhao,
Zhao, Sun, & Zhang, 2013).
Recently, a mutation in ATG5 was identified
in two siblings with congenital ataxia with
developmental delay and mental retardation.
This E122D mutation results in defects of the
conjugation of ATG5 to ATG12 and therefore
decreased autophagy. Introduction of the
corresponding mutation in a yeast system
resulted in a 30%50% reduction of induced
autophagy. A corresponding Drosophila model
replicated the ataxia phenotype, indicating a
causal link of the ATG5 mutation to the ataxia
phenotype (Kim et al., 2016).
Lysosomal Disorders
The lysosome has a central role in cellular
catabolism and in intracellular trafficking by
being at the crossroad between endocytic and
autophagic pathways. Given this, disruption of
this pathway at multiple points leads to
impaired lysosomal function and hence defec-
tive autophagosome turnover. This can result
not only from the accumulation of undegraded
autophagic components in the lysosome but
also accumulation of autophagosomes that
may fail to fuse with the lysosome. For exam-
ple, disruption of early endosomal function by
depletion of COPI leads to the accumulation of
autophagic structures that fail to reach the
lysosome (Razi, Chan, & Tooze, 2009).
Likewise, loss of function of the ESCRT
complex that is required for generation of
intraluminal vesicles in later endosomal
structures known as MVBs not only blocks
endocytic degradation but also leads to the
accumulation of autophagosomes (Rusten &
Stenmark, 2009). Thus, abnormal autophagic
flux can be consequence of primary endocytic
and lysosomal defects.
LSDs are rare, inherited disorders with
variable phenotypes. They represent the most
common cause of neurodegeneration in child-
hood but can also result in neurological
impairment in adults (Poupetova et al., 2010;
Wraith, 2002). Most LSDs are caused by loss-
of-function of specific lysosomal hydrolases,
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leading to the accumulation of the substrates
of these enzymes and accumulation of
general autophagic substrates due to impaired
autophagosomelysosome fusion (Ballabio &
Gieselmann, 2009; Platt, Boland, & van der
Spoel, 2012; Settembre et al., 2008). There is
increasing evidence that changes in membrane
lipid composition as a result of lysosomal
dysfunction contribute to lysosome fusion
defects. This process appears to be relevant to
LSDs, since LSD-associated membrane choles-
terol abnormalities have been shown to lead to
lysosomal accumulation of several substrates,
lysosomal dysfunction, and impairment of
endocytic membrane trafficking (Fraldi et al.,
2010). In mouse models of mucopolysacchari-
dosis type III (Sanfilippo syndrome), defects in
the breakdown of heparin sulfate cause an
altered membrane lipid composition, with
SNARE protein redistribution resulting in
impaired autophagosomelysosome fusion
and a block in autophagy (Fraldi et al., 2010;
Settembre et al., 2008).
In Krabbe disease, a defect of
β-galactocerebrosidase causes the accumulation
of the glycosphingolipid psychosine, which in
turn alters the lipid composition of cellular
membranes (Hawkins-Salsbury et al., 2013).
In NiemannPick type A disease, where muta-
tions in the gene encoding acid sphingomyeli-
nase cause accumulation of sphingomyelin,
defects in mATG9 trafficking and autophago-
some closure have also been observed
(Corcelle-Termeau et al., 2016). NiemannPick
type C disease is a sphingolipid storage disor-
der that results from inherited deficiencies in
intracellular lipid-trafficking proteins and is
characterized by an abnormal intracellular
accumulation of cholesterol and glycosphingo-
lipids (Lloyd-Evans & Platt, 2010). Similarly,
GM1 gangliosidosis and infantile neuronal
ceroid lipofuscinoses have been shown to be
associated with the occurrence of chronic ER
stress (Sano et al., 2009; Wei et al., 2008).
Sphingomyelin storage also leads to lysosomal
membrane permeabilization, thereby liberating
cathepsins into the cytosol (Serrano-Puebla &
Boya, 2015).
Defects in posttranslational modifications or
impaired trafficking of lysosomal enzymes or
defective acidification can also result in lyso-
somal dysfunction (Colacurcio & Nixon, 2016;
Hirst et al., 2015; Kyttala, Yliannala, Schu,
Jalanko, & Luzio, 2005; Morimoto et al., 1989;
Tiede et al., 2005). One example is represented
by multiple sulfatase deficiencies, in which a
failed posttranslational modification of sulfa-
tases by an ER-resident enzyme abrogates the
function of many lysosomal hydrolases (Dierks
et al., 2009). Furthermore, impaired lysosomal
structure, regeneration, fusion, and signaling
also contribute to lysosomal malfunction
(Blanz et al., 2010; Chang et al., 2014; Cortes
et al., 2014; Endo, Furuta, & Nishino, 2015; Yu
et al., 2010). For example, NiemannPick dis-
ease type C, caused by loss of NPC1 function,
leads to impaired Ca21 homeostasis and incor-
rect cholesterol trafficking with accumulation
of nonesterified cholesterol and glycosphingo-
lipids in late endosomes and lysosomes,
disrupting their fusion (Lloyd-Evans et al.,
2008; Lloyd-Evans & Platt, 2010; Pacheco &
Lieberman, 2008). More recently, mutations
in SNX14, encoding a sorting nexin
phosphoinositol-binding protein localized on
late endosome and lysosomal membranes
and involved in cargo sorting upon endocyto-
sis, were found in patients with hereditary
cerebellar ataxia. Autophagosome clearance
was slowed in patient cells, suggesting lyso-
someautophagosome dysfunction (Akizu
et al., 2015). A specific role of the autophago-
somelysosome fusion for lysosomal disease
pathology is further underlined by the discov-
ery of a homozygous missense mutation in
VPS11 in patients with a rare form of leukoen-
cephalopathy (Zhang et al., 2016). VPS11 is a
member of the homotypic fusion and protein
sorting and class C core vacuole/endosome
tethering complexes, and mutations lead to
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impaired autophagy. In zebrafish with a
null mutation of vps11, reduction in CNS mye-
lination and extensive neuronal death were
observed in the hindbrain and midbrain
(Zhang et al., 2016).
Finally, several studies have linked autop-
hagy to the regulated secretion of the contents
of secretory granules or lysosomes in special-
ized cells or tissues (Cadwell et al., 2008;
DeSelm et al., 2011; Michaud et al., 2011; Ushio
et al., 2011). Examples of such events at the
plasma-membrane include secretion of lyso-
zyme from Paneth cells, which is implicated in
Crohn’s disease (Cadwell et al., 2008), secretion
of ATP under certain conditions (Michaud
et al., 2011), secretion of cathepsin K by osteo-
clasts during bone resorption (DeSelm et al.,
2011), and the secretion of cytotoxic proteins
stored in the lytic granules of activated cyto-
toxic T lymphocytes (CTLs), which is a key
event in killing target cells (Ushio et al., 2011).
Most likely, the fusion events of autophagic
vesicles with the plasma-membrane (autopha-
gosome exocytosis) are mediated by SNAREs,
in a manner similar to lysosome and lysosome-
related organelles, such as lytic granules and
melanosomes. Indeed, this has been demon-
strated for the secretion of lytic granules:
patients with familial hemophagocytic lympho-
histiocytosis type 4 who have mutations in the
SNARE protein syntaxin-11 have impaired
degranulation of CTLs (Bryceson et al., 2007;
Hong, 2005). Moreover, recent findings suggest
a role for the SNARE proteins VAMP8 and
VTI1B (SNAREs that regulate autophagosome-
lysosome fusion) in the exocytosis of toxic
proteins stored in the lytic granules of CTLs
(Dressel, Elsner, Novota, Kanwar, & Fischer
von Mollard, 2010). During lysosomal exocyto-
sis, a Ca21-regulated process (mediated by the
activation of the lysosomal Ca21 channel
MCOLN1) enables lysosomes to dock to the
cell surface and fuse with the plasma-
membrane, emptying their contents outside the
cell. This process has an important role in
secretion and plasma-membrane repair.
Interestingly, lysosomal exocytosis is transcrip-
tionally regulated by TFEB, a master regulator
that coordinates lysosomal biogenesis and
autophagy (Sardiello et al., 2009; Settembre
et al., 2011), which promotes cellular clearance
in models of lysosomal storage diseases
(Medina et al., 2011). Therefore, it is tempting
to speculate that cells may use this mechanism
to coordinate autophagosomelysosome deg-
radative activity and autophagy-mediated
secretory functions in response to specific
stimuli, suggesting that promoting lysosomal
exocytosis may represent an alternative
strategy to treat disorders due to intracellular
storage, such as LSDs.
AUTOPHAGY UPREGULATION
While autophagy is essential for nervous
system function, data also supports it decreas-
ing with age across diverse organisms. A range
of approaches have been used to assess the
potential benefits of constitutive autophagy
upregulation in normal health and aging as
well as neurodegenerative disease contexts,
and these approaches support a clear associa-
tion of upregulation with beneficial effects.
Approaches within invertebrate model organ-
isms show that induction of autophagy with
spermidine extends lifespan in Drosophila and
Caenorhabditis elegans (Eisenberg et al., 2009).
Depletion of acetyl-coenzyme A through
knocking down its synthetase specifically in
the Drosophila brain also results in prolonged
lifespan with enhanced autophagy-mediated
protein clearance, which is likely the result of
decreasing inhibitory acetylation of autophagy
regulators (Eisenberg et al., 2014). Autophagy is
induced and lifespan extended by caloric restric-
tion in C. elegans (Hansen et al., 2008) as well as
by pan-neuronal overexpression of Atg8a or
AMPK in Drosophila (Simonsen et al., 2008;
Ulgherait, Rana, Rera, Graniel, & Walker, 2014).
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When assessing the mechanisms of how autop-
hagy upregulation enhances survival, studies in
C. elegans support the benefit acting through
diverse pathways, which include clearance and
turnover of mitochondria as well as ER homeo-
stasis and mitotic alterations (Ghavidel et al.,
2015; Palikaras, Lionaki, & Tavernarakis, 2015).
In mice, constitutive upregulation of autop-
hagy by ubiquitous overexpression of ATG5
results in extended lifespan and reduced aging
phenotypes. These include enhanced motor
performance, leanness and, at a primary cellu-
lar level, enhanced resistance to oxidative dam-
age (Pyo et al., 2013). Likewise, deletion of the
polyQ tract from mouse huntingtin increases
autophagy and results in lifespan extension
(Zheng et al., 2010).
In cells, autophagy upregulation enhances
the clearance of toxic aggregate-prone proteins,
such as mutant huntingtin, alpha-synuclein,
and tau (Berger et al., 2006; Ravikumar, Duden,
& Rubinsztein, 2002; Webb, Ravikumar, Atkins,
Skepper, & Rubinsztein, 2003). The process of
autophagic engulfment enables removal of
oligomeric species, which are inaccessible to
the proteasome. While the protective role of
autophagy has been widely replicated in ani-
mal models of various diseases caused
by intracytoplasmic aggregate-prone proteins
(Menzies, Fleming et al., 2015), most studies
in vivo have used chemical tools that likely
have autophagy-independent effects. However,
overexpression of Atg5 in zebrafish induces
autophagy and ameliorates tau toxicity (Lopez
et al., 2017). Likewise, genetic inhibition of
calpain protects against tau and huntingtin
toxicity in vivo in an autophagy-dependent
manner (Menzies, Garcia-Arencibia et al., 2015).
Since upregulation of autophagy has benefi-
cial effects, a number of pharmacological
autophagy stimulators have been identified
and tested in preclinical models of neurode-
generative diseases (Harris & Rubinsztein,
2011; Levine, Packer, & Codogno, 2015; Sarkar
& Rubinsztein, 2008). The most extensively
employed preclinical pharmacological tools to
probe autophagy modulation in neurodegen-
eration are trehalose and rapamycin.
Trehalose
Trehalose is a stable disaccharide assembled
from two molecules of D-glucose (Fig. 11.4).
Many organisms, notably fungi, insects, and
other invertebrates, biosynthesize trehalose
(Richards et al., 2002). Humans, like other mam-
mals, do not synthesize trehalose, but significant
quantities may be ingested as part of a normal
diet, and some can be absorbed (Kamiya,
Hirata, Matsumoto, Arai, & Yoshizane, 2004;
Murray, Coupland, Smith, Ansell, & Long,
2000; Richards et al., 2002).
Trehalose has been shown to have activity
in a variety of cellular and animal models of
neurodegeneration (Emanuele, 2014). Trehalose
treatment leads to decreased huntingtin aggre-
gation and reduced toxicity in vitro as well as
reduced aggregation and increased lifespan in
the R6/2 transgenic mouse model of HD
(Tanaka et al., 2004). Trehalose has also been
shown to reduce toxicity and formation of
mutant PABPN1 aggregates in a cellular
model of oculopharyngeal muscular dystrophy
(OPMD) and reduced aggregates and cell death
and improved disease-associated muscle weak-
ness in a mouse model of this disease (Davies,
Sarkar, & Rubinsztein, 2006). More recently,
trehalose has also been shown to decrease the
processing of both APP and of C-terminal frag-
ments derived from it, to reduce the secretion of
Aβ (Tien, Karaca, Tamboli, & Walter, 2016), and
to rescue impaired cognition and decrease Aβ
deposition in the APP/PS-1 mouse model (Du,
Liang, Xu, Sun, & Wang, 2013). Other studies
have shown effects in cell and mouse models
of tauopathy (Kruger et al., 2012; Schaeffer
et al., 2012), tauopathy with Parkin deletion
(Rodriguez-Navarro et al., 2010), SCA17 (Chen
et al., 2015), and ALS (Castillo, Nassif et al.,
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2013; Li et al., 2015; Zhang, Chen et al., 2014).
Mixed data has been reported in cell and animal
models of Lewy body disease (Tanji et al., 2015)
and prion disease (Aguib et al., 2009).
Mechanistically, trehalose has been identified
as an mTOR-independent enhancer of autop-
hagy (Sarkar, Davies, Huang, Tunnacliffe, &
Rubinsztein, 2007) signaling via AMPK.
Recently, DeBosch has proposed that trehalose
enhances autophagy through inhibition of
SLC2A (GLUT) transporters (DeBosch et al.,
2016). IC50 values against GLUT transporters
were reported as between 17.3 and 126 mM;
these values seem inconsistent with the early
reports of effects in cell assays at submillimolar
concentrations. A further study by this group
reports that GLUT8 functions as a trehalose-
transporter responsible for trehalose entry into
mammalian cells (Mayer et al., 2016).
An intravenous formulation of trehalose,
known as Cabaletta, has been developed by
Bioblast Pharma for the treatment of PolyA
and PolyQ diseases. Cabaletta is in Phase III
for OPMD and Phase II for SCA3. Preliminary
results from a 24-week open-label Phase II trial
have shown that Cabaletta improves dyspha-
gia and muscle function in OPMD (Argov,
Gliko-Kabir, Brais, Caraco, & Megiddo, 2016).
Rapamycin
Rapamycin, a macrolide antifungal and
immunosuppressant, was first discovered and
characterized as an autophagy activator over 20
years ago (Blommaart, Luiken, Blommaart, van
Woerkom, & Meijer, 1995; Heitman, Movva, &
Hall, 1991; Noda & Ohsumi, 1998). The
FIGURE 11.4 The chemical structures of selected autophagy enhancers with demonstrated in vivo efficacy in models
of neurodegeneration.
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mechanism of action of rapamycin involves
binding to FKBP12, and the resulting complex
interacts with mTORC1, inhibiting its kinase
activity through an allosteric mechanism
(Benjamin, Colombi, Moroni, & Hall, 2011;
Heitman et al., 1991). Functionally, mTOR forms
two complexes termed mTORC1 and mTORC2,
with rapamycin’s inhibitory action on mTOR
showing selectivity toward the first (Schreiber
et al., 2015). A significant effort has been
devoted toward the evolution of rapamycin
analogs (called “rapalogues”) as well as toward
the targeted development of more potent,
ATP-competitive inhibitors of mTOR, such as
Torin (Benjamin et al., 2011), these latter in par-
ticular as anticancer agents. However, Torin-
type inhibitors inhibit both mTORC1 and
mTORC2 complexes and display poor selectiv-
ity typically associated with ATP-competitive
kinase inhibitors, rendering them less
suitable for chronic indications.
Rapalogues (including rapamycin) have been
employed to probe the therapeutic benefit of
autophagy activation in a number of animal
models of neurodegeneration. In the triple-
transgenic AD mouse model, rapamycin as well
as mTOR genetic reduction was shown to res-
cue cognitive deficits and decrease Aβ and tau
pathology through autophagy stimulation
(Caccamo, De Pinto, Messina, Branca, & Oddo,
2014; Caccamo, Majumder, Richardson, Strong,
& Oddo, 2010). Prevention of AD-like cognitive
deficits and lowered levels of amyloid peptide
by rapamycin were reported in another AD
mouse model, the PDAPP mouse (Spilman
et al., 2010). In a model of prion disease, Cortes
et al. reported that rapamycin delayed disease
onset, increased survival, and ameliorated dis-
ease severity (Cortes, Qin, Cook, Solanki, &
Mastrianni, 2012). In the P301S TAU mouse
model, temsirolimus (a rapalogue) was shown
to reduce tau hyperphosphorylation and
improve spatial cognitive behavior (Jiang et al.,
2014). Similar effects were shown for rapamy-
cin in the same tau mouse model (Ozcelik
et al., 2013). Temsirolimus ameliorated motor
performance in a transgenic mouse model of
spinocerebellar ataxia type 3, inducing autop-
hagy and reducing the number of aggregates
and protein levels of mutant ataxin-3 (Menzies
et al., 2010), and ameliorated behavioral perfor-
mance and decreased aggregate formation in
the HD-N171-N82Q mouse model of HD
(Ravikumar et al., 2004). In a PD mouse model
(Parkin Q311X mice), rapamycin decreased
dopaminergic neuronal loss, reduced synuclein
levels, improved motor function, and induced
autophagic markers (Siddiqui et al., 2015).
While studies in many models of neurodegen-
erative diseases have converged on the therapeu-
tic efficacy of rapalogues, investigations in ALS
models have provided contradictory results. In
some studies, detrimental effects were reported
(Zhang et al., 2011) but beneficial effects were
subsequently observed after uncoupling of rapa-
mycin’s immunomodulatory function (Staats
et al., 2013). The possibility that the immuno-
modulatory role of rapalogues may contribute to
the phenotypic amelioration (or indeed worsen
the phenotype) observed in different animal
models of neurodegeneration remains a concern.
However, the rationale that autophagy activation
is therapeutically relevant in neurodegenerative
diseases is strongly supported by the ameliora-
tion observed with autophagy activators with
different mechanisms of action.
Repurposing of FDA-Approved Drugs
as Autophagy Upregulators
There have been many reports of using
repurposed FDA-approved drugs for the
treatment of neurodegenerative disorders via
upregulation of autophagy (Fleming, Noda,
Yoshimori, & Rubinsztein, 2011; Levine et al.,
2015; Rubinsztein, Bento, & Deretic, 2015).
Selected examples are presented here.
Metformin is a first-line antidiabetes drug
that has been demonstrated to upregulate
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autophagy in several preclinical animal models
of neurodegenerative diseases but with mixed
results on the outcome of disease progression.
This FDA-approved drug is CNS-penetrant
(Labuzek et al., 2010) and is an activator of
AMPK. Treatment of transgenic mice expres-
sing a mutant huntingtin with CAG repeat
length of 136151 (HD R6/2) with metformin
significantly increased brain AMPK phosphor-
ylation levels (Ma et al., 2007). Whilst
decreased hind limb clasping and increased
lifespan was observed in males, no effects were
observed in female mice. In vivo electrophysi-
ology demonstrated a significant increase in
survival of motor units in the SOD1G93A mouse
model of ALS, although beneficial effects were
seen in different muscles of male and female
mice (Kaneb, Sharp, Rahmani-Kondori, &
Wells, 2011). This effect was observed with
treated with 2 mg/mL metformin in drinking
water; however, doses of 0.5, 2, and 5 mg/mL
metformin did not significantly alter neurologi-
cal scores and did not increase survival or
delay disease onset in male mice. Indeed, met-
formin dose dependently worsened survival
rates for females, possibly owing to inhibition
of estrogen production (Kaneb et al., 2011).
In transgenic mice overexpressing human
AβPP 695 (Tg6799), metformin stimulated
autophagosome accumulation and promoted
the generation of Aβ through increased β- and
γ-secretase activity (Son et al., 2016). The
results of this study suggest that metformin
heightens the progression of AD by increasing
Aβ synthesis within autophagosomes.
The Bcr-Abl tyrosine kinase inhibitor niloti-
nib is approved for the treatment of chronic
myelogenous leukemia. The compound is
known to be CNS-penetrant but has a low con-
centration in cerebrospinal fluid (CSF)
(Reinwald et al., 2014). Nilotinib has been
shown to induce autophagy in vivo (Yu et al.,
2013) and increase amyloid clearance in an Aβ
transgenic mouse model (Lonskaya, Hebron,
Desforges, Schachter, & Moussa, 2014;
Lonskaya, Hebron, Selby, Turner, & Moussa,
2015).
A number of compounds that act on the
cAMP/IP3 pathway have shown benefits in
animal models of neurodegeneration, includ-
ing verapamil, clonidine, rilmenidine, and
minoxidil (Rose et al., 2010; Williams et al.,
2008). Verapamil is a calcium channel blocker
prescribed for the treatment of hypertension,
angina pectoris, and cardiac arrhythmia and
is known to penetrate the CNS (Narang,
Blumhardt, Doran, & Pickar, 1988). In a
Drosophila model of HD, verapamil slowed the
progression of the HD phenotype, and in a zeb-
rafish transgenic model of HD where expression
is driven in the rod photoreceptors, verapamil
reduced the number of aggregates compared
to untreated fish, leading to a reduction of pho-
toreceptor degeneration (Williams et al., 2008).
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